Success Metrics

Clinical Success Rate
60.0%

Based on 3 completed trials

Completion Rate
60%(3/5)
Active Trials
5(50%)
Results Posted
67%(2 trials)
Terminated
2(20%)

Phase Distribution

Ph early_phase_1
1
10%
Ph phase_1
4
40%
Ph phase_2
3
30%
Ph phase_3
1
10%

Phase Distribution

5

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution9 total trials
Early Phase 1First-in-human
1(11.1%)
Phase 1Safety & dosage
4(44.4%)
Phase 2Efficacy & side effects
3(33.3%)
Phase 3Large-scale testing
1(11.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

5

trials recruiting

Total Trials

10

all time

Status Distribution
Active(5)
Completed(3)
Terminated(2)

Detailed Status

Recruiting4
Completed3
Terminated2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
5
Success Rate
60.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (11.1%)
Phase 14 (44.4%)
Phase 23 (33.3%)
Phase 31 (11.1%)

Trials by Status

active_not_recruiting110%
recruiting440%
completed330%
terminated220%

Recent Activity

5 active trials
Showing 5 of 10
recruiting

Tau PET in Imaging and Cognition: Healthy Adults From 55-90

NCT03372317
active_not_recruitingphase_2

Transcranial Photobiomodulation for Alzheimer's Disease (TRAP-AD)

NCT04784416
completedphase_1

Alzheimer's PET Imaging in Racially/Ethnically Diverse Adults

NCT03706261
recruitingphase_2

Longitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer's Disease

NCT04576793
recruitingphase_1

R21 Roche: 3-Way Tau Tracers in AD

NCT05464368
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT03372317

Tau PET in Imaging and Cognition: Healthy Adults From 55-90

Recruiting
NCT04784416Phase 2

Transcranial Photobiomodulation for Alzheimer's Disease (TRAP-AD)

Active Not Recruiting
NCT03706261Phase 1

Alzheimer's PET Imaging in Racially/Ethnically Diverse Adults

Completed
NCT04576793Phase 2

Longitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer's Disease

Recruiting
NCT05464368Phase 1

R21 Roche: 3-Way Tau Tracers in AD

Recruiting
NCT06999434Phase 1

Exploring the Utility of [18F]3F4AP for Demyelination Imaging

Recruiting
NCT03373604Phase 2

Imaging Tau in Alzheimer's Disease and Normal Aging

Completed
NCT06860373Phase 3

LIFE-DSR-Biomarker Sub-study of Biomarkers in Down Syndrome Related Alzheimer's Disease (DS-AD)

Terminated
NCT03757910Early Phase 1

Brain Imaging in the Diabetes Prevention Program Outcomes Study

Terminated
NCT04566003Phase 1

Evaluation Comparing Tau PET Radiotracers, [18F]GTP1 and [18F]PI-2620 or [18F]MK-6240 in Subjects With Normal Cognition or Prodromal to Moderate Alzheimer's Disease

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10